Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Transformation Not Yet Complete, Says Departing R&D Chief
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
